中国药房2011，Vol.22Issue(22)：2069-2072,4.
重组人血小板生成素治疗难治性特发性血小板减少性紫癜的循证评价
Evidence-based Evaluation of Recombinant Human Thromobopoietin for Refractory Idiopathic Thrombocytopenic Purpura
黄琳 1任晓蕾 1刘一 1李玉珍1
作者信息
- 1. 北京大学人民医院药剂科,北京市,100044
- 折叠
摘要
Abstract
OBJECTIVE: To evaluate the efficacy and safety of recombinant human thromobopoietin (rhTPO) for adult chronic refractory idiopathic thrombocytopenic purpura (ITP).METHODS: By literature analysis based on evidence-based medicine, clinical trials about rhTPO in the treatment of adult chronic refractory ITP were retrieved from CMB, CNKI, MEDLINE, EMbase and Cochrane library.RESULTS: Of collected pertinent literature about rhTPO in the treatment of adult chronic refractory ITP, five were self-control studies and two were randomized controlled trials (RCTs).The quality of seven studies was evaluated according to Jadad scale, of which one scored four points, and the others below three points.The five self-control studies all supported that rhTPO could effectively elevate the platelet counts and was safe for patients with adult chronic refractory ITP.Two RCTs indicated that rhTPO combined with danazol was more effective than danazol for adult chronic refractory ITP, and rhTPO was still effective for patients with adult chronic refractory ITP who failed with dauazol.CONCLUSION: It has been demonstrated that rhTPO is effective and safe for adult chronic refractory ITP.Good large-scale sample study is required because of the shortage of experimental design.关键词
重组人血小板生成素/特发性血小板减少性紫癜/有效/安全Key words
Recombinant human thromobopoictin/ Refractory idiopathic thrombocytopenic purpura/ Efficacy/ Safety分类
医药卫生引用本文复制引用
黄琳,任晓蕾,刘一,李玉珍..重组人血小板生成素治疗难治性特发性血小板减少性紫癜的循证评价[J].中国药房,2011,22(22):2069-2072,4.
